Thrombosis in Medical Technology
Navigation Links
Thrombosis in Medical Technology
... today at the XXII International Society on thrombosis and Haemostasis Congress in Boston. Edoxaban is ... established by the International Society on thrombosis and Haemostasis(3), the most sensitive scale of ... products in non-surgical patients. Journal of thrombosis and Haemostasis 2005;3: 692-694.
...
... being developed for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery. The decision ... the XXII Congress of the International Society on thrombosis and Haemostasis (ISTH) on July 15, 2009 in ... this product candidate." About Deep Vein thrombosis (DVT) DVT is caused when a blood clot ...
... for TAXUS, p-value=0.092)*. No stent thrombosis between two and three years with XIENCE V, and a low rate of stent thrombosis from zero to three years, per Academic Research ... (ARC) definition of definite/probable stent thrombosis (0.9 percent for XIENCE V and 2.8 percent for ...
... flights aren't the only risk factor for deep vein thrombosis (DVT), the medical term for blood clots in the ... For most healthy adults, deep vein thrombosis is extremely rare. Every year, about 350,000 ... are used to diagnose DVT. Treatment for deep vein thrombosis seeks to prevent the clot from becoming bigger ...
... an important anti-platelet therapy in treating thrombosis patients in both the acute and chronic settings." ... receptor on platelets has been proven to prevent thrombosis and subsequent heart attacks. Portola believes ... ischemic events, and elective PCI. About thrombosis Thrombosis, or the development of harmful ...
... arterial thromboembolic events (i.e., deep-vein thrombosis of the lower and upper limbs, visceral and ... i n the Treat m ent of Deep-Venous thrombosis (EQUINOX Study): Safety, Efficacy, and ... patients with symptomatic and confirmed deep-vein thrombosis were randomized to receive weekly subcutaneous ...
... receptor on platelets has been proven to prevent thrombosis and subsequent heart attacks. Portola believes ... of Cardiovascular Research at the Center for thrombosis Research at Sinai Hospital, Baltimore, MD. ... achieved the predefined endpoint. Inhibition of thrombosis was highly significant in these non-responder ...
... TAXUS, p-value=0.03)*. -- Low rates of stent thrombosis between one and two years, defined as very late ... (ARC) definition of definite/probable stent thrombosis (0.5 percent for XIENCE V and 0.8 percent for TAXUS). The ARC definitions of stent thrombosis were developed to eliminate variability in the ...
... The adjusted rate of ARC definite/probable stent thrombosis at three years for the TAXUS Liberte Stent group ... adjusted rate of ARC definite/probable stent thrombosis for the direct stent group at 0.3 percent, as ... of 46 percent. ARC definite/probable total stent thrombosis at two years was 0.8 percent for the TAXUS ...
... MPH to reduce the number of cases of deep vein thrombosis and pulmonary embolism in the United States. ... Pulmonary Section, blood clots, called deep vein thrombosis (DVT), can occur after periods of being immobile, ... and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial. Lancet. ...
... re-intervention (TLR) (2.5%). The definite stent thrombosis rate was 0.8 percent after one year, which is ... stent-related composite cardiac events and stent thrombosis were 4.3 percent and 0.9 percent respectively. ... "The low occurrence of cardiac events and stent thrombosis is noteworthy, especially given the high degree ...
... reduced risk of heart attack and stent thrombosis compared with clopidogrel among ... was also a significantly lower rate of stent thrombosis among diabetes patients treated with prasugrel, ... in a 48 percent relative risk reduction in stent thrombosis compared with clopidogrel (3.6 percent vs. 2.0 ...
... peripheral conditions related to arterial thrombosis with a novel mechanism that may provide ... novel mechanism of action. About Thrombosis thrombosis is the formation of a clot, or thrombus, inside a ... and efficacy of APD791; the role of serotonin in thrombosis and in increasing cardiovascular risk; how ...
... Long-Term Clinical Outcomes, Lower Rates of Stent thrombosis than Patients Treated ... lower observed rates of late and very late stent thrombosis in XIENCE V-treated patients, especially in those ... for TAXUS, p-value=0.07)*. -- Low rates of stent thrombosis between one and two years, defined as very ...
... both BMS and DES at the time of enrollment. Stent thrombosis was a pre-defined secondary endpoint in the ... reduced the relative risk of coronary stent thrombosis (a new clot at the implanted stent site) over ... research consortium (ARC) definition of stent thrombosis was used - definite/confirmed stent thrombosis, ...
... (NYSE: SGP ) and The Sinai Center for thrombosis Research at Sinai Hospital of Baltimore today ... Paul Gurbel, MD, Director of The Sinai Center for thrombosis Research, Sinai Hospital of Baltimore; ... Blood work was processed at The Sinai Center for thrombosis Research and the University of Oklahoma Health ...
... a difference in either acute (30 day) or late thrombosis rates between XIENCE V and TAXUS out to one year. ... a statistical difference between rates of stent thrombosis for XIENCE V or TAXUS out to one year in the SPIRIT III trial. Rates of late stent thrombosis at one year per protocol were 0.3 percent for ...
... analysis reported the overall incidence of stent thrombosis in the data set using the Academic Research ... and definite/probable/possible stent thrombosis rates for the CYPHER(R) Stent at three years were ... 5.3 percent and 6.4 percent, respectively. Stent thrombosis comparisons between the CYPHER(R) Stent and the ...
... the REALITY Trial investigators reported a stent thrombosis rate for the Taxus Stent that was significantly ... the difference between the protocol-defined stent thrombosis rate for each drug-eluting stent in the diabetic ... death, Q-wave myocardial infarction and stent thrombosis favoring the CYPHER(R) Stent were also seen in ...
... the bare-metal control experienced one stent thrombosis during this same period. This marks the third consecutive year of TAXUS II follow-up with no stent thrombosis seen in the TAXUS stent patient group. The ... data regarding late and very late stent thrombosis out to five years," said Prof. Sigmund ...
... difference between their rates of stent thrombosis (blood clots). "The five-year results of the ... a significant difference in the rates of stent thrombosis between the CYPHER(R) Stent and the bare metal ... were used, the rates of acute and subacute stent thrombosis were 0.0 percent for the bare metal stent and 1.1 ...
... that Soliris substantially reduced the risk of thrombosis in a diverse population of PNH ... the course of the disease.(3,4,5,6) An initial thrombosis increases the relative risk of death by five- to ... hemolysis in all treated patients and reduced thrombosis by 92 percent, with three events during Soliris ...
... Taxus(R) Liberte stent in high risk of restenosis patients. However, the thrombosis rate for Taxus treated patients increased from one to two years from 4.2% ... at 658 days in a patient who had previously presented with a subacute thrombosis and who was on dual antiplatelet therapy at the time of both thromboses. ...
... or its components, including death, repeat heart attack, stroke or stent thrombosis at one year. "The HORIZONS AMI trial provided outcomes data showing ... individual rates of death, repeat heart attack, stroke and stent thrombosis between the two groups through 12 months of follow-up, which persisted ...
... blood. Platelets serve a central role in forming pathological arterial thrombosis that causes myocardial infarction and stroke. The study's authors further ... to identify postmenopausal women with an increased risk of arterial thrombosis or clotting before even starting estrogen therapy is an important goal to ...
... that the device was absorbed. In addition, there were no cases of thrombosis (blood clot formation) out to two years of follow-up, and no new major ... Key endpoints of the study include assessments of safety - MACE and stent thrombosis rates - at 30 days; six, nine, 12 and 18 months; and two years, with ...
... option," said Richard Becker, MD, director of the Duke Cardiovascular thrombosis Center and lead author of the study. "TRA appears to work in a novel way ... which demonstrate the potential to address unmet medical needs. thrombosis may result in partial or complete blockage of arteries in the heart, brain ...
... evaluated using guidelines established by the International Society on thrombosis and Haemostasis(1), the most sensitive scale of those currently used in ... of antihemostatic medicinal products in non-surgical patients. Journal of thrombosis and Haemostasis 2005;3: 692-694. 2. Jorgensen, H.S., Nakayama, ...
... were a target lesion revascularization (TLR) rate of 5%, a subacute thrombosis (SAT) rate of 0.4%, a late stent thrombosis (LST) rate of 0.3%, and a major adverse cardiac events (MACE) rate of ....
... follow-up data from the ATLANTA Trial. The results include zero percent thrombosis in patients discontinuing dual anti-platelet therapy after only 30 days. ... FIM patient population, the results showed zero (0.0) percent stent thrombosis (Academic Research Consortium, or ARC-defined), death, myocardial ...
... being developed for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery. The decision ... the XXII Congress of the International Society on thrombosis and Haemostasis (ISTH) on July 15, 2009 in ... this product candidate." About Deep Vein thrombosis (DVT) DVT is caused when a blood clot ...
Isis and Collaborators Present New Research at the ATVB Annual Conference
... data were presented during the Arteriosclerosis, thrombosis and Vascular Biology's (ATVB) Annual Conference. ... drug candidate for development from our new thrombosis effort. It is another example of the power of ... Factor XI as the optimal target to inhibit thrombosis without causing bleeding. In addition to Factor ...... for TAXUS, p-value=0.092)*. No stent thrombosis between two and three years with XIENCE V, and a low rate of stent thrombosis from zero to three years, per Academic Research ... (ARC) definition of definite/probable stent thrombosis (0.9 percent for XIENCE V and 2.8 percent for ...
... flights aren't the only risk factor for deep vein thrombosis (DVT), the medical term for blood clots in the ... For most healthy adults, deep vein thrombosis is extremely rare. Every year, about 350,000 ... are used to diagnose DVT. Treatment for deep vein thrombosis seeks to prevent the clot from becoming bigger ...
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
... p-value=0.07)*. -- Low rates of stent thrombosis (blood clotting within the treated area) per the ... (ARC) definition of definite/probable stent thrombosis (1.3 percent for XIENCE V vs. 1.7 percent for ... percent for TAXUS). The ARC definitions of stent thrombosis were developed to eliminate variability in the ...... an important anti-platelet therapy in treating thrombosis patients in both the acute and chronic settings." ... receptor on platelets has been proven to prevent thrombosis and subsequent heart attacks. Portola believes ... ischemic events, and elective PCI. About thrombosis Thrombosis, or the development of harmful ...
... arterial thromboembolic events (i.e., deep-vein thrombosis of the lower and upper limbs, visceral and ... i n the Treat m ent of Deep-Venous thrombosis (EQUINOX Study): Safety, Efficacy, and ... patients with symptomatic and confirmed deep-vein thrombosis were randomized to receive weekly subcutaneous ...
... receptor on platelets has been proven to prevent thrombosis and subsequent heart attacks. Portola believes ... of Cardiovascular Research at the Center for thrombosis Research at Sinai Hospital, Baltimore, MD. ... achieved the predefined endpoint. Inhibition of thrombosis was highly significant in these non-responder ...
... TAXUS, p-value=0.03)*. -- Low rates of stent thrombosis between one and two years, defined as very late ... (ARC) definition of definite/probable stent thrombosis (0.5 percent for XIENCE V and 0.8 percent for TAXUS). The ARC definitions of stent thrombosis were developed to eliminate variability in the ...
... The adjusted rate of ARC definite/probable stent thrombosis at three years for the TAXUS Liberte Stent group ... adjusted rate of ARC definite/probable stent thrombosis for the direct stent group at 0.3 percent, as ... of 46 percent. ARC definite/probable total stent thrombosis at two years was 0.8 percent for the TAXUS ...
... MPH to reduce the number of cases of deep vein thrombosis and pulmonary embolism in the United States. ... Pulmonary Section, blood clots, called deep vein thrombosis (DVT), can occur after periods of being immobile, ... and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial. Lancet. ...
Surgeon General's 'Call to Action' to Prevent DVT/PE Praised by NATT as Turning Point
... -- The National Alliance for thrombosis and Thrombophilia (NATT) praised Acting ... to Action" (CTA) to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). RADM Galson ... NC In the past year, CDC has designated thrombosis as a priority, increasing surveillance of DVT/PE ...... re-intervention (TLR) (2.5%). The definite stent thrombosis rate was 0.8 percent after one year, which is ... stent-related composite cardiac events and stent thrombosis were 4.3 percent and 0.9 percent respectively. ... "The low occurrence of cardiac events and stent thrombosis is noteworthy, especially given the high degree ...
... reduced risk of heart attack and stent thrombosis compared with clopidogrel among ... was also a significantly lower rate of stent thrombosis among diabetes patients treated with prasugrel, ... in a 48 percent relative risk reduction in stent thrombosis compared with clopidogrel (3.6 percent vs. 2.0 ...
... peripheral conditions related to arterial thrombosis with a novel mechanism that may provide ... novel mechanism of action. About Thrombosis thrombosis is the formation of a clot, or thrombus, inside a ... and efficacy of APD791; the role of serotonin in thrombosis and in increasing cardiovascular risk; how ...
Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women
... the prevention and management of thrombosis in key patient populations and reinforce ... on the challenges in preventing and treating thrombosis in pregnant women and children, and on managing ... are used to prevent and treat thrombosis or blood clotting that arises in arteries, veins, ...... Long-Term Clinical Outcomes, Lower Rates of Stent thrombosis than Patients Treated ... lower observed rates of late and very late stent thrombosis in XIENCE V-treated patients, especially in those ... for TAXUS, p-value=0.07)*. -- Low rates of stent thrombosis between one and two years, defined as very ...
TRITON-TIMI 38 Stent Analysis Favors Prasugrel
... since the stenting procedure, or the way stent thrombosis is defined. The results of the TRITON-TIMI 38 ... Overall, prasugrel reduced both early stent thrombosis -- within 30 days of stenting -- when compared ... hazard ratio 0.41, p<0.001) -- and late stent thrombosis -- more than 30 days after stenting (0.49 percent ...Study Finds Repeated Episodes of Stent Thrombosis Common
... Treating stent thrombosis with another stent hikes the risk of repeat blood ... attack or even death. A single incident of stent thrombosis is bad enough, but a new study suggests that one ... total of 437 consecutive patients who had stent thrombosis confirmed by angiography between January 2004 and ...... both BMS and DES at the time of enrollment. Stent thrombosis was a pre-defined secondary endpoint in the ... reduced the relative risk of coronary stent thrombosis (a new clot at the implanted stent site) over ... research consortium (ARC) definition of stent thrombosis was used - definite/confirmed stent thrombosis, ...
Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH
... Continued to Be Associated with Reductions in thrombosis and Improvements in Fatigue, Quality of Life, and ... was associated with sustained reduction in thrombosis and improvements in fatigue, overall quality of ... in Transfusion Requirements, Fatigue and thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal ...... (NYSE: SGP ) and The Sinai Center for thrombosis Research at Sinai Hospital of Baltimore today ... Paul Gurbel, MD, Director of The Sinai Center for thrombosis Research, Sinai Hospital of Baltimore; ... Blood work was processed at The Sinai Center for thrombosis Research and the University of Oklahoma Health ...
Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
... rates of death, myocardial infarction, and stent thrombosis across a broad cross section of patients and lesions and with no new cases of stent thrombosis between years four and five," said Gregg W. ... the TAXUS IV trial reported no cases of stent thrombosis between years four and five for the TAXUS Stent ...... a difference in either acute (30 day) or late thrombosis rates between XIENCE V and TAXUS out to one year. ... a statistical difference between rates of stent thrombosis for XIENCE V or TAXUS out to one year in the SPIRIT III trial. Rates of late stent thrombosis at one year per protocol were 0.3 percent for ...
... analysis reported the overall incidence of stent thrombosis in the data set using the Academic Research ... and definite/probable/possible stent thrombosis rates for the CYPHER(R) Stent at three years were ... 5.3 percent and 6.4 percent, respectively. Stent thrombosis comparisons between the CYPHER(R) Stent and the ...
... the REALITY Trial investigators reported a stent thrombosis rate for the Taxus Stent that was significantly ... the difference between the protocol-defined stent thrombosis rate for each drug-eluting stent in the diabetic ... death, Q-wave myocardial infarction and stent thrombosis favoring the CYPHER(R) Stent were also seen in ...
... the bare-metal control experienced one stent thrombosis during this same period. This marks the third consecutive year of TAXUS II follow-up with no stent thrombosis seen in the TAXUS stent patient group. The ... data regarding late and very late stent thrombosis out to five years," said Prof. Sigmund ...
... difference between their rates of stent thrombosis (blood clots). "The five-year results of the ... a significant difference in the rates of stent thrombosis between the CYPHER(R) Stent and the bare metal ... were used, the rates of acute and subacute stent thrombosis were 0.0 percent for the bare metal stent and 1.1 ...
... that Soliris substantially reduced the risk of thrombosis in a diverse population of PNH ... the course of the disease.(3,4,5,6) An initial thrombosis increases the relative risk of death by five- to ... hemolysis in all treated patients and reduced thrombosis by 92 percent, with three events during Soliris ...
Value of Genetic Testing for Preventing Blood Clots Unproven, According to New AHRQ Study
... a history of blood clots helps to prevent a condition known as deep-vein thrombosis or to improve other clinical outcomes. The report, a summary of which ... As many as 600,000 Americans each year may have deep-vein thrombosis -- blood clots that form in the legs or pelvis. The condition occurs most ...... Taxus(R) Liberte stent in high risk of restenosis patients. However, the thrombosis rate for Taxus treated patients increased from one to two years from 4.2% ... at 658 days in a patient who had previously presented with a subacute thrombosis and who was on dual antiplatelet therapy at the time of both thromboses. ...
... or its components, including death, repeat heart attack, stroke or stent thrombosis at one year. "The HORIZONS AMI trial provided outcomes data showing ... individual rates of death, repeat heart attack, stroke and stent thrombosis between the two groups through 12 months of follow-up, which persisted ...
... blood. Platelets serve a central role in forming pathological arterial thrombosis that causes myocardial infarction and stroke. The study's authors further ... to identify postmenopausal women with an increased risk of arterial thrombosis or clotting before even starting estrogen therapy is an important goal to ...
... that the device was absorbed. In addition, there were no cases of thrombosis (blood clot formation) out to two years of follow-up, and no new major ... Key endpoints of the study include assessments of safety - MACE and stent thrombosis rates - at 30 days; six, nine, 12 and 18 months; and two years, with ...
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
... the following key results: A zero percent rate of stent thrombosis (blood clot formation) for all patients out to two years of follow up. ... Key endpoints of the study include assessments of safety - MACE and stent thrombosis rates - at 30 days, six, nine and 18 months, and one and two years, with ...... option," said Richard Becker, MD, director of the Duke Cardiovascular thrombosis Center and lead author of the study. "TRA appears to work in a novel way ... which demonstrate the potential to address unmet medical needs. thrombosis may result in partial or complete blockage of arteries in the heart, brain ...
... evaluated using guidelines established by the International Society on thrombosis and Haemostasis(1), the most sensitive scale of those currently used in ... of antihemostatic medicinal products in non-surgical patients. Journal of thrombosis and Haemostasis 2005;3: 692-694. 2. Jorgensen, H.S., Nakayama, ...
... were a target lesion revascularization (TLR) rate of 5%, a subacute thrombosis (SAT) rate of 0.4%, a late stent thrombosis (LST) rate of 0.3%, and a major adverse cardiac events (MACE) rate of ....
... follow-up data from the ATLANTA Trial. The results include zero percent thrombosis in patients discontinuing dual anti-platelet therapy after only 30 days. ... FIM patient population, the results showed zero (0.0) percent stent thrombosis (Academic Research Consortium, or ARC-defined), death, myocardial ...
Other ContentscarotenoidscarotenoidsreleasereleasereleasereleasereleasereleasereleasereleasereleasetunneltunneltunneltunneltunnelceliacceliaccarpalcarpalcarpalcastrationcastrationcataractscataractscataractscathetercathetercathetercathetercathetercatheterOther TagsbreastfeedInauguratePlacedexams
(Date:11/24/2009)...h . , The presence of increased body fat, an...es in the blood, hinders the loss and maintenance ...the University of Navarra conducted by Estbaliz Go...cy. , The project, entitled "A nutrigenetic and ...ody weight and inflammation," examines how the ind...
(Date:11/23/2009)...iated strain of the deadly superbug MRSAan infecti...ioticsposes a far greater health threat than previ...according to a study in the December issue of Eme... easily picked up in fitness centers, schools, and... burden of MRSA within hospitals, the report found...
(Date:11/23/2009)...me of day matters to forest trees dealing with dro...rch team led by Professor Malcolm Campbell, Univer...esearch and colleagues in the department of cell a... Capitalizing on their previous work to decode the...ined how poplar trees use their 45,000 genes to re...
Breaking Biology News(10 mins):It can be predicted the reaction obese patients will have to a diet 2New study finds MRSA on the rise in hospital outpatients 2Time of day matters to thirsty trees, U of T researcher discovers 2Case Western Reserve University receives 243 7M NIH grant to study autonomic nervous system link to painful bladder syndrome 52572 1Case Western Reserve University receives 243 7M NIH grant to study autonomic nervous system link to painful bladder syndrome 52572 2Short stressful events may improve working memory 9335 1Short stressful events may improve working memory 9335 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 9330 1Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 9330 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 9330 3(Date:11/28/2009)...iation believed to affect circadian rhythm, , ...ew research suggests that an internal body clock t...elopment of bipolar disorder in children. , Th...tic makeup of 152 children with bipolar disorder, ...ings, and 140 children without the disorder. They ...
(Date:11/27/2009)...BC, Nov. 27 /PRNewswire/ - Uploadable USB pedomete...me in wellness. A combination of advanced accelero...solving a long term concern over the accuracy of s... gauge and reward improved participation in a fitn...of the first wellness suppliers to integrate this ...
(Date:11/27/2009)...ISCO, Nov. 27 The Gymbor...ir Lambert, CFO/COO, will present at the NASDAQ OM... May Fair Hotel in London, England, on Wednesday, ...en to a live broadcast of The Gymboree Corporation...o www.gymboree.com, click on "Our Company" at the ...
(Date:11/27/2009)...HAMIR, Israel, Nov. 27 S...amir" ), a leading provider of innovative products...ounced today that its board of directors had decla... of US$ 10 million (approximately NIS 37.62 millio...te of exchange), or approximately US$ 0.609 (appro...
(Date:11/27/2009)...ng unprecedented medical, economic burdens, study ...News) -- The number of people with diabetes in the... 25 years, a new study predicts. , That would b...e with the disease, up from 23.7 million today. ,...with diabetes will triple, the study also warns, r...
Breaking Medicine News(10 mins):Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3[0] Bipolar Disorder May Be Tied to Body Clock[0] New USB technology adds accountability and convenience to wellness programs[0] The Gymboree Corporation to Present at NASDAQ OMX 23rd Investor Program[0] Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend[0] Diabetes Cases Expected to Double in 25 Years
breastfeedclericShiainsistedGuitaristAllowancesInaugurateTrainersfundraisingPlacedexamsCampsAccordanceCommercialisation
Other Tagstypical 2typical 3typical 4typical 5typical 6typical 7typical 8typical 9typical 10assistant 2assistant 3assistant 4assistant 5assistant 6assistant 7assistant 8assistant 9assistant 10toward 2toward 3toward 4toward 5toward 6toward 7toward 8toward 9toward 10guiding 2guiding 3warming 2warming 3warming 4warming 5suffer 2suffer 3suffer 4suffer 5suffer 6suffer 7suffer 8suffer 9suffer 10
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |